XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination. This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.
创建时间：
2005-07-15
